Drug General Information (ID: DDI9XDPZY1)
Drug Name			Clofibrate		Drug Info		Furosemide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antihyperammonia Agents				Diuretics
Structure

Mechanism of Clofibrate-Furosemide Interaction (Severity Level: Minor)
Competitive binding of plasma proteins Click to Show/Hide Mechanism Graph
Drug Name		Clofibrate				Furosemide
Mechanism		Competition for plasma protein binding sites				Competition for plasma protein binding sites
Key Mechanism Factor 1
		Factor Name		Plasma protein binding
		Factor Description		Plasma protein binding refers to the degree of binding of a drug to proteins in the blood, and the lower the degree of binding, the more efficiently the drug can cross cell membranes or diffuse. Plasma protein binding alters the distribution and therapeutic characteristics of the drugs.
Mechanism Description		Increased plasma concentration of Furosemide and Clofibrate due to competitive binding of plasma proteins

References
1	Bridgman JF, Rosen SM, Thorp JM "Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia." Lancet 2 (1972): 506-9. [PMID: 4115569]
2	Prandota J, Pruitt AW "Furosemide binding to human albumin and plasma of nephrotic children." Clin Pharmacol Ther 17 (1975): 159-66. [PMID: 235396]
3	Product Information. Atromid-S (clofibrate). Wyeth-Ayerst Laboratories, Philadelphia, PA.